Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

Authors

  • Nishi Kothari Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
  • Richard Kim Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
  • Robert N. Jorissen Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia
  • Jayesh Desai Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
  • Jeanne Tie Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medical Oncology, The Western Hospital, Footscray, Victoria, Australia
  • Hui-Li Wong Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
  • Ian Farragher Department of Medical Oncology, The Western Hospital, Footscray, Victoria, Australia
  • Ian Jones Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
  • Fiona L. Day Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
  • Shan Li Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia
  • Anuratha Sakthinandeswaren Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia
  • Michelle Palmieri Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia
  • Lara Lipton Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medical Oncology, The Western Hospital, Footscray, Victoria, Australia
  • Michael Schell Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
  • Jamie K. Teer Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
  • David Shibata Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
  • Timothy Yeatman Oncology Research, Gibbs Cancer Center and Research Institute, Spartanburg, USA
  • Oliver M. Sieber Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia
  • Peter Gibbs Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medical Oncology, The Western Hospital, Footscray, Victoria, Australia; BioGrid Australia, Parkville, Victoria, Australia
  • Ben Tran Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medical Oncology, The Western Hospital, Footscray, Victoria, Australia

DOI:

https://doi.org/10.3109/0284186X.2014.990158

Abstract

Background. Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC.

Patients and methods. Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression.

Results. From a cohort of 1487 CRC patients, 185 patients harbored a PIK3CA mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34–92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant.

Conclusions. Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2015-04-21

How to Cite

Kothari, N., Kim, R., Jorissen, R. N., Desai, J., Tie, J., Wong, H.-L., … Tran, B. (2015). Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncologica, 54(4), 487–492. https://doi.org/10.3109/0284186X.2014.990158

Issue

Vol. 54 No. 4 (2015): Acta Oncologica

Section

Articles